<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250314</url>
  </required_header>
  <id_info>
    <org_study_id>P070121</org_study_id>
    <nct_id>NCT01250314</nct_id>
  </id_info>
  <brief_title>Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density</brief_title>
  <acronym>OSTEHOM</acronym>
  <official_title>Radiological, Biological, Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rational: Osteoporosis in men is responsible for one third of fragility fractures. However&#xD;
      the definition and especially the determinants of fracture in humans are less well known than&#xD;
      in women.&#xD;
&#xD;
      Primary Objective: To search radiologic, biochemical, genetic and micro-architecture bone&#xD;
      factors associated to fractures in men with low bone density.&#xD;
&#xD;
      Study design: case/control study (fracture vs. no fracture) with men selected according to&#xD;
      low bone density (Z-score&lt;-2).&#xD;
&#xD;
      Eligibility criteria: Included subjects will be men whose age is ³ 40 and £ 70 years with a&#xD;
      Z-score&lt; -2 at least at one of the 3 measured sites (wrist, lumbar spine, femoral neck).&#xD;
      Subjects with secondary osteoporosis will be excluded (corticosteroid treatment,&#xD;
      hypogonadism, …) Progress of the study: The recruitment will be over two years. The study&#xD;
      will include two periods, an inclusion visit and a period of 3 months to achieve radiological&#xD;
      and biological examinations. The subjects will be recruited in the 3 rheumatology departments&#xD;
      (LARIBOISIERE, COCHIN). Subjects will be investigated at LARIBOISIERE hospital to perform&#xD;
      radiological examinations and biological sampling for laboratory tests within 3 months of&#xD;
      enrollment.&#xD;
&#xD;
      Evaluation criteria: Biochemistry: dosages of sexual steroids, bone remodeling markers and&#xD;
      homocysteine; Genetic: evaluation of polymorphism of candidates genes associated to fragility&#xD;
      fractures (collagen type I, homocysteine, LRP5); Radiology: evaluation of bone&#xD;
      micro-architecture with a scan of lumbar spine and hip and peripheral micro-scan (XTREME&#xD;
      sSCANCO) and bone densitometry at spine, femoral neck and wrist.&#xD;
&#xD;
      Duration of participation: there is no follow up Total duration of the study: 2 years and 3&#xD;
      months. Number of subjects: 100 patients with fracture and 100 controls without fracture&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statistical Analysis: Relationship between computed scan parameters at different sites, bone&#xD;
      micro-architectural parameters (peripheral scan), biological parameters, genetic markers and&#xD;
      the occurrence of fracture will be analyzed initially by univariate analysis (screening&#xD;
      process). This will help to reduce the number of variables analyzed at the second stage of&#xD;
      analysis (i.e. multivariate analysis).&#xD;
&#xD;
      Expected results: This study will help to evaluate radiological, biochemical and genetic&#xD;
      determinants of bone quality in men with decreased bone density. It will help to establish a&#xD;
      prospective study to evaluate predictive factors of fractures in men.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Sexual steroid dosages, bone remodeling markers, homocysteine, IGF1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Polymorphism evaluation of candidate genes associated to fractures of fragility (collagen type I, receptor of 25-hydroxy vitamin D, aromatase, MTHFR, LRP5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Bone micro-architecture evaluation with a scanner examination of lumbar spine and hip, peripheral scanner (Xtreme Scanco) and bone mineral densitometry at spine, femoral neck and wrist.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>With fracture</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with fracture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without fracture</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients without fracture</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiology</intervention_name>
    <description>Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).</description>
    <arm_group_label>With fracture</arm_group_label>
    <arm_group_label>Without fracture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological, biochemical and genetic samples</intervention_name>
    <description>*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone&#xD;
Urinary samples :&#xD;
Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample&#xD;
*Assessment of possible determinants of fractures in man&#xD;
Blood samples plasma (5 ml):&#xD;
Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH&#xD;
Homocysteine&#xD;
IGF1&#xD;
Extraction of DNA for a genetic polymorphism study:&#xD;
Sample of 10 ml of blood on EDTA for DNA extraction.&#xD;
Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor&#xD;
Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way.</description>
    <arm_group_label>With fracture</arm_group_label>
    <arm_group_label>Without fracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject of masculine gender&#xD;
&#xD;
          -  Aged ≥ 40 years and ≤ 70 years&#xD;
&#xD;
          -  Subject with Z-score &lt; -2 at least one of 3 sites&#xD;
&#xD;
          -  one of 3 sites (wrists, lumbar spine (defined on at least 2 continuous evaluable&#xD;
             vertebrae between L1-L4) and femoral neck) discovered incidentally or not&#xD;
&#xD;
          -  Subject who have signed the informed consent form&#xD;
&#xD;
        The inclusion densitometry examination, less than 6 months old, will be performed on a&#xD;
        Lunar or Hologic system. The reference data are the French reference data included in the&#xD;
        Lunar system and TK in the Hologic system).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient or control subject with no affiliation at health national system (beneficiary&#xD;
             or co-beneficiary)&#xD;
&#xD;
          -  Subject who received any corticoid treatment more than 3 months along&#xD;
&#xD;
          -  Subject with any known seropositivity for HIV&#xD;
&#xD;
          -  Subject with a chronic inflammation disease (rheumatoid polyarthritis, ankylosing&#xD;
             spondylarthritis, inflammatory bowel)&#xD;
&#xD;
          -  Subject with secondary osteoporosis documented by clinical and biological examinations&#xD;
             (serum calcium, serum phosphate, serum phosphatase alkaline, gamma GT, testosterone)&#xD;
             in order to eliminate any chronic alcoholism, alcoholic cirrhosis, hypogonadism,&#xD;
             osteomalacia, hemochromatosis, hyperthyroidism, primitive hyperparathyroidism,&#xD;
             hypercorticism&#xD;
&#xD;
          -  Subject who received treatment with bisphosphonates intravenously&#xD;
&#xD;
          -  Subject who received a treatment with bisphosphonates (Actonel® or Fosamax®) for at&#xD;
             least 5 years and stopped since less than 2 years&#xD;
&#xD;
          -  Subject who received a treatment with bisphosphonates for at least 3 years and stopped&#xD;
             since less than 1 year&#xD;
&#xD;
          -  Subject who received a treatment with bisphosphonates during the 6 months before&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Christine De VERNEJOUL, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fédération de Rhumatologie - Hôpital LARIBOISIERE</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>November 27, 2010</study_first_submitted>
  <study_first_submitted_qc>November 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>July 1, 2012</last_update_submitted>
  <last_update_submitted_qc>July 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>men</keyword>
  <keyword>bone micro-architecture</keyword>
  <keyword>bone markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

